[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
JAMA Insights
Clinical Update
June 12, 2018

Antithrombotic Therapy for Peripheral Artery Disease in 2018

Author Affiliations
  • 1Division of Cardiology, Department of Medicine, University of Colorado School of Medicine and CPC Clinical Research, Aurora
JAMA. 2018;319(22):2329-2330. doi:10.1001/jama.2018.5422

Peripheral artery disease (PAD) commonly refers to lower extremity atherosclerosis and is estimated to affect more than 200 million people worldwide.1 Patients with PAD are at increased risk for major adverse cardiac events (MACE) (myocardial infarction [MI], ischemic stroke, and cardiovascular death) and major adverse limb events (MALE) (major amputation and acute limb ischemia). Among patients with symptomatic PAD, annual rates of MACE are 4% to 5%, and rates of MALE are 1% to 2%.2 These ischemic events are associated with increased platelet and thrombotic activity and are potentially mitigated by antiplatelet therapy, anticoagulant therapy, or both. Based on available evidence, antithrombotic therapies should be individualized based on clinical presentation.